Intermediate nemaline myopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:171433OMIM:609284G71.2
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Intermediate nemaline myopathy (also called nemaline myopathy, intermediate form) is a rare inherited neuromuscular disorder that falls within the spectrum of nemaline myopathies — a group of congenital myopathies characterized by the presence of rod-shaped structures (nemaline bodies) in muscle fibers on biopsy. The intermediate form is classified between the severe congenital form and the typical congenital form in terms of clinical severity. It primarily affects the skeletal muscular system, leading to significant muscle weakness and hypotonia (reduced muscle tone) that is evident from birth or early infancy. Affected individuals typically achieve some motor milestones but often with significant delay; independent ambulation may be achieved in some cases but is frequently lost over time, and many patients become wheelchair-dependent during childhood or adolescence. Key clinical features include generalized muscle weakness predominantly affecting proximal muscles, respiratory insufficiency that often requires ventilatory support (ranging from nocturnal non-invasive ventilation to continuous mechanical ventilation), feeding difficulties, facial weakness, and a high-arched palate. Bulbar muscle weakness can contribute to swallowing difficulties and poor weight gain. Joint contractures and scoliosis may develop over time. Respiratory complications are a major source of morbidity and mortality in this form. Cardiac involvement is generally not a prominent feature, distinguishing nemaline myopathies from some other congenital myopathies. Intermediate nemaline myopathy can be caused by mutations in several genes involved in thin filament structure and function, including NEB (nebulin), ACTA1 (skeletal muscle alpha-actin), TPM3, and others. There is currently no cure or disease-modifying treatment available. Management is supportive and multidisciplinary, focusing on respiratory care (including ventilatory support), nutritional support (which may include gastrostomy tube feeding), physical therapy to maintain mobility and prevent contractures, orthopedic management of scoliosis and joint deformities, and regular monitoring of respiratory function. Early and proactive respiratory management has been shown to improve survival and quality of life.

Clinical phenotype terms— hover any for plain English:

Nemaline bodiesHP:0003798Severe muscular hypotoniaHP:0006829Myopathic faciesHP:0002058HypokinesiaHP:0002375Type 1 muscle fiber predominanceHP:0003803Multiple prenatal fracturesHP:0005855
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Intermediate nemaline myopathy.

View clinical trials →

No actively recruiting trials found for Intermediate nemaline myopathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Intermediate nemaline myopathy community →

No specialists are currently listed for Intermediate nemaline myopathy.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Intermediate nemaline myopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Intermediate nemaline myopathyForum →

No community posts yet. Be the first to share your experience with Intermediate nemaline myopathy.

Start the conversation →

Latest news about Intermediate nemaline myopathy

No recent news articles for Intermediate nemaline myopathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Intermediate nemaline myopathy

What is Intermediate nemaline myopathy?

Intermediate nemaline myopathy (also called nemaline myopathy, intermediate form) is a rare inherited neuromuscular disorder that falls within the spectrum of nemaline myopathies — a group of congenital myopathies characterized by the presence of rod-shaped structures (nemaline bodies) in muscle fibers on biopsy. The intermediate form is classified between the severe congenital form and the typical congenital form in terms of clinical severity. It primarily affects the skeletal muscular system, leading to significant muscle weakness and hypotonia (reduced muscle tone) that is evident from birt

At what age does Intermediate nemaline myopathy typically begin?

Typical onset of Intermediate nemaline myopathy is neonatal. Age of onset can vary across affected individuals.